147 related articles for article (PubMed ID: 28912960)
1. Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists.
Hifinger M; Hiligsmann M; Ramiro S; Watson V; Berghea F; Péntek M; Keat A; Severens JL; Fautrel B; Boonen A
RMD Open; 2017; 3(2):e000453. PubMed ID: 28912960
[TBL] [Abstract][Full Text] [Related]
2. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
Hifinger M; Hiligsmann M; Ramiro S; Watson V; Severens JL; Fautrel B; Uhlig T; van Vollenhoven R; Jacques P; Detert J; Canas da Silva J; Scirè CA; Berghea F; Carmona L; Péntek M; Keat A; Boonen A
Ann Rheum Dis; 2017 Jan; 76(1):126-132. PubMed ID: 27190098
[TBL] [Abstract][Full Text] [Related]
3. Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists.
Hifinger M; Hiligsmann M; Ramiro S; Severens JL; Fautrel B; Watson V; Boonen A
Rheumatology (Oxford); 2017 Jan; 56(1):68-76. PubMed ID: 28028156
[TBL] [Abstract][Full Text] [Related]
4. What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis.
Díaz-Torné C; Urruticoechea-Arana A; Ivorra-Cortés J; Díaz S; Dilla T; Sacristán JA; Inciarte-Mundo J; Comellas M; Prades M; Lizán L
Adv Ther; 2020 Apr; 37(4):1479-1495. PubMed ID: 32088860
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.
Husni ME; Betts KA; Griffith J; Song Y; Ganguli A
Rheumatol Int; 2017 Sep; 37(9):1423-1434. PubMed ID: 28623526
[TBL] [Abstract][Full Text] [Related]
6. Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.
Kuijper TM; Folmer R; Stolk EA; Hazes JMW; Luime JJ
Arthritis Res Ther; 2017 Apr; 19(1):78. PubMed ID: 28446212
[TBL] [Abstract][Full Text] [Related]
7. Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making.
Harrison M; Bansback N; Aguiar M; Koehn C; Shojania K; Finckh A; Hudson M
Clin Rheumatol; 2020 Oct; 39(10):2931-2941. PubMed ID: 32248434
[TBL] [Abstract][Full Text] [Related]
8. Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania.
Simons G; Veldwijk J; DiSantostefano RL; Englbrecht M; Radawski C; Bywall KS; Valor Méndez L; Hauber B; Raza K; Falahee M
Rheumatology (Oxford); 2023 Feb; 62(2):596-605. PubMed ID: 36068022
[TBL] [Abstract][Full Text] [Related]
9. Impact of falling reimbursement rates on physician preferences regarding drug therapy for osteoarthritis using a discrete choice experiment.
Berchi C; Degieux P; Halhol H; Danel B; Bennani M; Philippe C
Int J Pharm Pract; 2016 Apr; 24(2):114-22. PubMed ID: 26383231
[TBL] [Abstract][Full Text] [Related]
10. What matters to patients and physicians when considering biologic therapy for rheumatoid arthritis.
Lisicki R; Chu L
Postgrad Med; 2008 Sep; 120(3):154-60. PubMed ID: 18824833
[TBL] [Abstract][Full Text] [Related]
11. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
[TBL] [Abstract][Full Text] [Related]
12. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making.
Bolge SC; Goren A; Brown D; Ginsberg S; Allen I
Patient Prefer Adherence; 2016; 10():1079-90. PubMed ID: 27390518
[TBL] [Abstract][Full Text] [Related]
13. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment.
Augustovski F; Beratarrechea A; Irazola V; Rubinstein F; Tesolin P; Gonzalez J; Lencina V; Scolnik M; Waimann C; Navarta D; Citera G; Soriano ER
Value Health; 2013; 16(2):385-93. PubMed ID: 23538191
[TBL] [Abstract][Full Text] [Related]
14. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
15. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.
Hiligsmann M; Dellaert BG; Dirksen CD; Watson V; Bours S; Goemaere S; Reginster JY; Roux C; McGowan B; Silke C; Whelan B; Diez-Perez A; Torres E; Papadakis G; Rizzoli R; Cooper C; Pearson G; Boonen A
Rheumatology (Oxford); 2017 Jul; 56(7):1167-1176. PubMed ID: 28398547
[TBL] [Abstract][Full Text] [Related]
16. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
17. Development of an Interactive Tool to Support Shared Decision-Making in Rheumatoid Arthritis: Treatment Attribute Preference.
Curtis JR; Ford K; Fiore S; Mikuls TR; Shaney K; Sethi V
Arthritis Care Res (Hoboken); 2024 Feb; 76(2):181-190. PubMed ID: 37652871
[TBL] [Abstract][Full Text] [Related]
18. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment.
Hazlewood GS; Bombardier C; Tomlinson G; Thorne C; Bykerk VP; Thompson A; Tin D; Marshall DA
Rheumatology (Oxford); 2016 Nov; 55(11):1959-1968. PubMed ID: 27477807
[TBL] [Abstract][Full Text] [Related]
19. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis.
Fraenkel L; Nowell WB; Michel G; Wiedmeyer C
Ann Rheum Dis; 2018 May; 77(5):678-683. PubMed ID: 29247126
[TBL] [Abstract][Full Text] [Related]
20. High dose chemotherapy and hematopoietic stem cell transplantation: a study of treatment preference in patients with rheumatoid arthritis and rheumatologists.
Verburg RJ; Mahabali SD; Stiggelbout AM; Sont JK; van Laar JM
J Rheumatol; 2002 Aug; 29(8):1653-8. PubMed ID: 12180724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
